Palo Alto, CANCT05068674Now EnrollingIRB Ready

Chronic Ischemic Left Ventricular Dysfunction Clinical Trial in Palo Alto, CA

Access cutting-edge chronic ischemic left ventricular dysfunction treatment through this phase 1 clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.

Sponsored by Joseph C. Wu

Quick Self-Assessment

See if you qualify for this Palo Alto location

Preparing your pre-screening questions…

Expert Care in Palo Alto

Access chronic ischemic left ventricular dysfunction specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related chronic ischemic left ventricular dysfunction treatment provided free

Apply for This Palo Alto Location

Check if you qualify for this chronic ischemic left ventricular dysfunction clinical trial in Palo Alto, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Palo Alto

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Palo Alto site if eligible
  4. 4Begin participation

About This Chronic Ischemic Left Ventricular Dysfunction Study in Palo Alto

This clinical study will utilize a new cell therapy approach (Human embryonic stem cells derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with chronic left ventricular dysfunction secondary to MI (Myocardial Infarction).

Sponsor: Joseph C. Wu

Who Can Participate

Inclusion Criteria

Be ≥ 21 and \< 80 years of age.
Provide written informed consent.
Have a diagnosis of chronic ischemic left ventricular dysfunction secondary to MI as defined by previous myocardial infarction documented by an imaging study demonstrating coronary artery disease with corresponding areas of akinesis, dyskinesis, or severe hypokinesis.
Be a candidate for cardiac catheterization within 5 to 10 weeks of screening.
Have been treated with appropriate maximal medical therapy for heart failure or postinfarction left ventricular dysfunction. For beta-blockade, the patient must have been on a stable dose of a clinically appropriate beta-blocker for 3 months. For angiotensinconverting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) or angiotensin receptor neprilysin inhibitors (ARNIs) or have appropriate medical indication precluding use of one or both of these agents, the patient must have been on a stable dose of a clinically appropriate agent for 1 month or within no more than doubling the dose of any of ARB, ACE inhibitors, and ARNIs over the last 3 months.
Left ventricular ejection fraction below 40%.
Class II/III NYHA symptoms of heart failure within the 6 months prior to baseline testing.
Hospitalization in the past 6 months or NT pro-BNP \> 1200 pg/mL, or \>1600 pg/mL if atrial fibrillation was present.
Automated implantable cardioverter-defibrillator (AICD) in place.

Exclusion Criteria

Have a baseline glomerular filtration rate \< 35 ml/min/1.73 m2
Have a known, serious radiographic contrast allergy.
Have a prosthetic aortic valve or heart constrictive device.
Have a documented presence of aortic stenosis (aortic stenosis graded as 1.5 cm2 or less).
Have a documented presence of moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ≥+2).
Have evidence of a life-threatening arrhythmia in the absence of a defibrillator (nonsustained ventricular tachycardia ≥ 20 consecutive beats or complete second- or third-degree heart block in the absence of a functioning pacemaker) or QTc interval \> 550 ms on screening ECG.
AICD firing in the past 60 days prior to enrollment.
Be eligible for or require coronary artery revascularization.
Have a hematologic abnormality as evidenced by hematocrit \< 25%, white blood cell \< 2,500/µl, or platelet values \< 100,000/µl without another explanation.
Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the ULN.
Have a coagulopathy (INR \> 1.3) not due to a reversible cause (i.e., Coumadin). Patients on Coumadin will be withdrawn 5 days before the procedure and confirmed to have an INR \< 1.3. Patients who cannot be withdrawn from Coumadin will be excluded from enrollment.
Have known allergies to penicillin or streptomycin.
Be an organ transplant recipient.
Have a history of organ or cell transplant rejection.
Have a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease-free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma.
Have a non-cardiac condition that limits lifespan to \< 1 year.
Be on chronic therapy with immunosuppressant medication, such as corticosteroids or TNFα antagonists.
Be serum-positive for HIV, hepatitis BsAg, or viremic hepatitis C.
Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.
Be a female patient who is pregnant, nursing, or have child-bearing potential but is not using effective birth control.
Tested positive for SARS-CoV-2 within the last 30 days

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Palo Alto?

Yes, this clinical trial (NCT05068674) has an active research site in Palo Alto, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Ischemic Left Ventricular Dysfunction Treatment Options in Palo Alto, CA

If you're searching for chronic ischemic left ventricular dysfunction treatment options in Palo Alto, CA, this clinical trial (NCT05068674) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Palo Alto research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced chronic ischemic left ventricular dysfunction specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic ischemic left ventricular dysfunction clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Palo Alto, CA

See all heart attack clinical trials recruiting in Palo Alto — not just this study.

Browse Heart Attack Trials in Palo Alto →

Browse More Trials by Condition

Heart Attack TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Palo Alto?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Palo Alto, CA